Incyte (INCY) · povorcitinib
Narrower window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: 2026
Phase 3 data are anticipated in 2026
EX-99.1 · filed · SEC filing
After
Stated timing: fourth quarter of 2026
Data from the Phase 3 studies (STOP-PN1 and STOP-PN2) evaluating povorcitinib in patients with moderate to severe prurigo nodularis (PN) are anticipated in the fourth quarter of 2026
SEC original · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/INCY-povorcitinib-2026-07-28, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/INCY-povorcitinib-2026-07-28
Incyte (INCY) pipeline and stated timing · Calendar · Companies A–Z